Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating Pin1 as a genetic modifier in Li-Fraumeni syndrome

FY 2013-14

Summary
Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome, that is, a genetic condition that places individuals at increased risk of developing cancer. LFS is characterized by multiple, early-onset malignant tumors, including cancers of the breast, brain, muscles, bones, and other organs. The majority of individuals with LFS have mutations in a critical gene called p53. p53, also known as ‘the guardian of the genome’ is a ‘tumor suppressor gene’, which is responsible for directing cells to either repair themselves, or to die, if they incur damage to their DNA. In patients with p53 mutations, this protective function is impaired, and as a result, they have an extraordinarily high lifetime risk of developing cancer – up to 73% in men and 100% in women. One of our great challenges is finding ways to predict which patients will get which type of tumors, and who will get cancers in childhood, early adulthood, or late adulthood. This is important to understand, so that we can target surveillance strategies specifically to the individual patient’s risk profile, and so that we can possibly use medications to prevent cancers in the future. Our group has previously shown that surveillance protocols can detect tumors at an early, pre-symptomatic stage in patients with LFS, and that as a result, their survival from cancer is improved. We would like to further refine these protocols to increase their utility and efficacy. In order to do so, we need to better understand each patient’s specific cancer risk. Our objective is to determine whether other genes work with p53 to influence a patient’s specific cancer risk in LFS. Other researchers have determined that a gene called Pin1 works with mutant p53 to promote tumor development and more aggressive tumor properties. We seek to determine the status of Pin1 in patients with LFS, in order to determine whether changes in Pin1 could explain why certain individuals get more aggressive cancers than others. First, we will use DNA samples from 107 patients with LFS to sequence their Pin1 gene. We will look for mutations, or changes in the Pin1 DNA sequence, and correlate these findings with the type of tumor the patient has, their age at diagnosis, their specific p53 mutation, and their clinical outcome. Second, we will look at blood cells derived from these same patients to study how the mutated Pin1 is expressed, and to test whether its activity is changed. Finally, we will determine whether these Pin1 variants are able to make cells become cancerous faster, and whether these cancers show more aggressive properties. This research will ultimately help us to improve outcomes for patients with this devastating cancer predisposition syndrome. Lessons we learn here can also be applied to patients with sporadic (non-inherited) cancers, since mutant p53 plays an important role in the development of many common tumors in the population.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311725
Name
Villani Anita
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating Pin1 as a genetic modifier in Li-Fraumeni syndrome
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Predisposition; Genetic Modifier; Li-Fraumeni Syndrome; P53; Pin1
Abstract
Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome, that is, a genetic condition that places individuals at increased risk of developing cancer. LFS is characterized by multiple, early-onset malignant tumors, including cancers of the breast, brain, muscles, bones, and other organs. The majority of individuals with LFS have mutations in a critical gene called p53. p53, also known as ‘the guardian of the genome’ is a ‘tumor suppressor gene’, which is responsible for directing cells to either repair themselves, or to die, if they incur damage to their DNA. In patients with p53 mutations, this protective function is impaired, and as a result, they have an extraordinarily high lifetime risk of developing cancer – up to 73% in men and 100% in women. One of our great challenges is finding ways to predict which patients will get which type of tumors, and who will get cancers in childhood, early adulthood, or late adulthood. This is important to understand, so that we can target surveillance strategies specifically to the individual patient’s risk profile, and so that we can possibly use medications to prevent cancers in the future. Our group has previously shown that surveillance protocols can detect tumors at an early, pre-symptomatic stage in patients with LFS, and that as a result, their survival from cancer is improved. We would like to further refine these protocols to increase their utility and efficacy. In order to do so, we need to better understand each patient’s specific cancer risk. Our objective is to determine whether other genes work with p53 to influence a patient’s specific cancer risk in LFS. Other researchers have determined that a gene called Pin1 works with mutant p53 to promote tumor development and more aggressive tumor properties. We seek to determine the status of Pin1 in patients with LFS, in order to determine whether changes in Pin1 could explain why certain individuals get more aggressive cancers than others. First, we will use DNA samples from 107 patients with LFS to sequence their Pin1 gene. We will look for mutations, or changes in the Pin1 DNA sequence, and correlate these findings with the type of tumor the patient has, their age at diagnosis, their specific p53 mutation, and their clinical outcome. Second, we will look at blood cells derived from these same patients to study how the mutated Pin1 is expressed, and to test whether its activity is changed. Finally, we will determine whether these Pin1 variants are able to make cells become cancerous faster, and whether these cancers show more aggressive properties. This research will ultimately help us to improve outcomes for patients with this devastating cancer predisposition syndrome. Lessons we learn here can also be applied to patients with sporadic (non-inherited) cancers, since mutant p53 plays an important role in the development of many common tumors in the population.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Villani, Anita
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~